CompletedPhase 3

Clinical Trial to Assess the Efficacy and Safety of YYD601 in the Treatment of Esophageal Reflux Disease (ERD)

South Korea170 participantsStarted 2019-01-29

Plain-language summary

A randomized, double-blind, double-dummy, active comparator, multi-centers, non-inferiority design clinical trial to assess the efficacy and safety of YYD601 in ERD patients (phase 3).

Who can participate

Age range20 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Experienced above 2 days in 1 week, Heartburn of acid regurgitation above the weakness.
✓. Experienced above 1 day in 1 week, Heartburn of acid regurgitation above the middle.

What they're measuring

LA grade 0(zero)

Timeframe: within 8 weeks

Trial details

NCT IDNCT03943992

SponsorYooyoung Pharmaceutical Co., Ltd.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2020-01-31

View on ClinicalTrials.gov More Erosive Esophagitis trials